Patents by Inventor Beverly E. Girten

Beverly E. Girten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of erectile dysfunction using isoquinoline compound melanocortin receptor ligands
    Patent number: 6608082
    Abstract: Methods for treating erectile dysfunction using tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: August 19, 2003
    Assignee: Lion Bioscience AG
    Inventors: Amaresh Basu, Timothy C. Gahman, Beverly E. Girten, Michael C. Griffith, Curtis C. Hecht, John S. Kiely, Sandra R. Slivka
  • Melanocortin receptor-3 ligands to treat sexual dysfunction
    Patent number: 6534503
    Abstract: Methods for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X1—X2-(D)Phe-Arg-(D)Trp-X3. A particularly useful compound is HP-228, which has the formula Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH2. The invention also provides methods for selecting melanocortin receptor-3 ligands by determining whether a compound modulates the activity of MC-3 as an agonist or antagonist. These methods can be used to screen compound libraries for ligands to treat MC-3-associated conditions. Such conditions include sexual dysfunction, including erectile dysfunction and sexual arousal disorder.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: March 18, 2003
    Assignee: Lion Bioscience AG
    Inventors: Kevin C. Dines, Timothy C. Gahman, Beverly E. Girten, Douglas L. Hitchin, Kevin R. Holme, Hengyuan Lang, Sandra R. Slivka, Karen J. Watson-Straughan, Ronald R. Tuttle, Yazhong Pei
  • Melanocortin receptor ligands and methods of using same
    Patent number: 6350430
    Abstract: The invention provides ligands for melanocortin receptors. For example, the invention provides the melanocortin receptor peptide ligand Ac-Nlc-Gln-His-(p(I)-D-Phe)-Arg-(D-Trp)-Cly-NH2, (SEQ ID NO: 1), where the iodo group is unlabeled or radioactively labeled. The invention additionally provides methods of assaying for melanocortin receptors in a cell or tissue such as brain. The invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a melanocortin receptor ligand and to methods of administering the pharmaceutical composition to a subject. The invention further provides tetrapeptide ligands for melanocortin receptors and methods of altering melanocortin receptor activity.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: February 26, 2002
    Assignee: Lion Bioscience Science AG
    Inventors: Colette T. Dooley, Beverly E. Girten, Richard A. Houghten
  • HP-3228 and related peptides to treat sexual dysfunction
    Patent number: 6284735
    Abstract: Methods for treating erectile dysfunction in males and sexual dysfunction, such as sexual arousal disorder, in females. The methods involve administering an effective dose of certain compounds, such as HP-228, having the generic formula X1-X′2-(D)Phe-Arg-(D)Trp-X3.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: September 4, 2001
    Assignee: Lion Bioscience AG
    Inventors: Beverly E. Girten, Ronald R. Tuttle
  • Cytokine restraining agents
    Patent number: 6245738
    Abstract: The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: June 12, 2001
    Assignee: Trega Biosciences, Inc.
    Inventors: Mark J. Suto, Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Ronald R. Tuttle
  • Isoquinoline compound melanocortin receptor ligands and methods of using same
    Patent number: 6127381
    Abstract: The invention relates to melanocortin receptor ligands and methods of using the ligands to alter or regulate the activity of a melanocortin receptor. The invention further relates to tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands and as agents for controlling cytokine-regulated physiologic processes and pathologies, and combinatorial libraries thereof.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: October 3, 2000
    Inventors: Amaresh Basu, Timothy C. Gahman, Beverly E. Girten, Michael C. Griffith, Curtis C. Hecht, John S. Kiely, Sandra R. Slivka
  • Use of cytokine restraining agents to treat inflammatory bowel disease
    Patent number: 5888969
    Abstract: The present invention relates to the use of cytokine restraining agents to treat inflammatory bowel disease.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: March 30, 1999
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Ronald R. Tuttle
  • Method for reducing the severity of gastro-intestinal damage
    Patent number: 5888978
    Abstract: The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: March 30, 1999
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Paul Omholt, Ronald R. Tuttle
  • Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
    Patent number: 5786332
    Abstract: The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: July 28, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Mark J. Suto, Ronald R. Tuttle
  • Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
    Patent number: 5760001
    Abstract: The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 2, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Mark J. Suto, Ronald R. Tuttle
  • Use of a cytokine regulatory agent to treat rheumatoid arthritis
    Patent number: 5741774
    Abstract: The present invention relates to the use of a cytokine regulatory agent to reduce the severity of rheumatoid arthritis.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: April 21, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Ronald R. Tuttle
  • Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
    Patent number: 5726156
    Abstract: The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: March 10, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Ali Andalibi, Amaresh Basu, Patrick Fagan, Richard A. Houghten, Costas C. Loullis, Paul Omholt, Ronald R. Tuttle, Mark J. Suto, Patricia A. Weber
  • Use of a substituted 1,3-benzodioxole to reduce a wasting condition
    Patent number: 5597843
    Abstract: The present invention provides a method of reducing a wasting condition, which can occur due to a pathology or to a particular physiologic or metabolic state in a subject, by administering to the subject a substituted 1,3-benzodioxole.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 28, 1997
    Assignee: Houghten Pharmaceuticals
    Inventors: Beverly E. Girten, Ronald R. Tuttle
  • Cytokine restraining agents
    Patent number: 5420109
    Abstract: The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: May 30, 1995
    Assignee: Houghten Pharmaceuticals, Inc.
    Inventors: Mark J. Suto, Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Ronald R. Tuttle